secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001641489-23-000046
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics gets Nasdaq extension to Dec 2023; must reverse split by Nov 22
--------------------------------------------------------------------------------

- Nasdaq extended bid price compliance deadline to December 18, 2023.
- Company must effect reverse stock split (1:10 to 1:20) by November 22, 2023.
- Stockholder approval for reverse split required by October 30, 2023.
- No assurance reverse split will ensure compliance; stock price impact uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000046/0001641489-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000046/vtvt-20230717.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer